Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(5): 257-261
DOI: 10.1055/s-2005-837553
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Is There Any Connection Between the Presence of Kidney Stones in Primary Hyperparathyroidism and the Location of an Underlying Adenoma?

E. Csupor1 , 3 , E. Toth2 , S. Meszaros3 , V. Ferencz3 , J. Szucs3 , P. Lakatos3 , J. Horányi4 , F. Perner5 , C. Horvath3
  • 1Health Service, Budavar Local Authorities, Budapest, Hungary
  • 2Department of Rheumatology, Ferenc Flor County Hospital, Kerepestarcsa, Hungary
  • 31st Department of Internal Medicine, Faculty of Medicine, Semmelweis University Medical School, Budapest, Hungary
  • 41st Department of Surgery, Faculty of Medicine, Semmelweis University, Budapest, Hungary
  • 5Department of Transplantation and Surgery, Faculty of Medicine, Semmelweis University, Budapest, Hungary
Further Information

Publication History

Received: July 2, 2004 First decision: October 14, 2004

Accepted: November 19, 2004

Publication Date:
30 May 2005 (online)

Also available at
    Permissions and Reprints

Abstract

The majority of the patients with primary hyperparathyroidism (pHPT) recurrently produce kidney stones, while the rest have other clinical manifestations. The aim of this study was to examine the possibility of an association between the presence of kidney stones and the location of an underlying adenoma. This was a retrospective evaluation of the records of 91 patients (10 males, 81 females, mean age: 61.9 years [20 - 70 yrs]) operated for primary hyperparathyroidism between 1995 and 2000. One patient was excluded due to carcinoma. Kidney stones were found in 55 cases and other clinical symptoms in 35 cases. In 50 of the 55 patients (91 %) with kidney stones, the adenoma was located in the left inferior parathyroid gland (χ² = 67.5, p < 0.00,001), while in 24 of the 35 patients (69 %) without kidney stones, the adenoma was in the right inferior parathyroid gland (χ² = 43.9, p < 0.0001). These results suggest that the location of the adenoma may influence the presence of kidney stones in pHPT. It is proposed that the biologic effects of parathyroid hormone could differ depending on which of the four parathyroid glands it was secreted in, or the four glands may produce different biologically active fragments.

Key words

Primary hyperparathyroidism - kidney stones - location of adenoma

References

  • 1 Alvarez-Arroyo M V, Traba M L, Rapado A, De La Piedra C. Role of citric acid in primary hyperparathyroidism with renal lithiasis.  Urol Res. 1992;  20 88-90
    CrossrefPubMedGoogle Scholar
  • 2 Ander S, Johansson K, Smeds S. Blood supply and parathyroid hormone secretion in pathological parathyroid glands.  World J Surg. 1996;  20 598-601
    PubMedGoogle Scholar
  • 3 Aurbach G D, Marx S J, Spiegel A M. Parathyroid hormone, calcitonin, and the calciferols. Wilson JD, Foster DW Textbook of Endocrinology. 8th ed. Philadelphia; WB Saunders Company 1992: 1397-1477
    Google Scholar
  • 4 Chen Z, Xu P, Barbier J R, Willick G, Ni F. Solution structure of the osteogenic 1 - 31 fragment of human parathyroid hormone.  Biochemistry. 2000;  39 12766-12777
    CrossrefPubMedGoogle Scholar
  • 5 Chou F F, Wang P W, Sheen-Chen S M. Preoperative localization of parathyroid glands in primary hyperparathyroidism.  Eur J Surg. 1997;  163 889-895
    PubMedGoogle Scholar
  • 6 D'Angelo A, Calo L, Cantaro S. Calciotropic hormones and nephrolithiasis.  Miner Electrolyte Metab. 1997;  23 269-272
    PubMedGoogle Scholar
  • 7 Dong-Ming S, Ellis S, Napier A, Lee K, Manley N R. Hoxa 3 and Pax1 regulate epithelial cell death and proliferation during thymus and parathyroid organogenesis.  Dev Biol. 2001;  236 316-329
    CrossrefPubMedGoogle Scholar
  • 8 Frokjaer V G, Mollerup C L. Primary hyperparathyroidism: renal calcium excretion in patients with and without renal stone disease before and after parathyroidectomy.  World J Surg. 2002;  26 532-535
    CrossrefPubMedGoogle Scholar
  • 9 Hirasawa T, Nakamura T, Mizushima A, Morita M, Ezawa I, Miyakawa H, Kudo Y. Adverse effects of an active fragment of parathyroid hormone on rat hippocampal organotypic cultures.  Br J Pharmacol. 2000;  129 21-28
    CrossrefPubMedGoogle Scholar
  • 10 Irvin G L, Carneiro D M. Management changes in primary hyperparathyroidism.  JAMA. 2000;  284 934-936
    CrossrefPubMedGoogle Scholar
  • 11 Khan A, Bilezikian J. Primary hyperparathyroidism: path physiology and impact on bone.  Can Med Assoc J. 2001;  163 184-187
    PubMedGoogle Scholar
  • 12 Koslin D B, Adams P, Everts E, Cohen J. Preoperative evaluation of patients with primary hyperparathyroidism: role of high resolution ultrasound.  Laryngoscope. 1997;  107 1249-1253
    PubMedGoogle Scholar
  • 13 Le H N, Norton J A. Surgical management of hyperparathyroidism. DeGroot LJ, Jameson JL Endocrinology. 4th ed. Philadelphia; Saunders Company 2001: 111-113
    Google Scholar
  • 14 Lesser T, Bartel M. Primary hyperparathyroidism. Pathogenesis diagnosis-therapy.  Zentralbl Chir. 1992;  117 41-49
    PubMedGoogle Scholar
  • 15 Lumachi F, Zucchetta P, Varotto S, Polistina F, Favia G, D'Amico D. Noninvasive localization procedures in ectopic hyperfunctioning parathyroid tumors.  Endocr-Relat Cancer. 1999;  6 123-125
    PubMedGoogle Scholar
  • 16 Luts L, Bergenfelz A, Aluments J, Sundler F. Peptide-containing nerve fibres in normal human parathyroid glands and in human parathyroid adenomas.  Eur J Endocrinol. 1995;  133 543-551
    PubMedGoogle Scholar
  • 17 Manley N R, Capecchi M. Hox group 3 para logs regulate the development and migration of the thymus, thyroid and parathyroid glands.  Dev Biol. 1998;  195 1-15
    CrossrefPubMedGoogle Scholar
  • 18 Marx S J. Medical progress: hyper parathyroid and hypo parathyroid disorders.  N Engl J Med. 2000;  343 1863-1875
    CrossrefPubMedGoogle Scholar
  • 19 Marx U C, Adermann K, Bayer P, Frossmann W G, Rosch P. Solution structures of human parathyroid hormone fragments hPTH(1 - 34) and hPTH(1 - 39) and bovine parathyroid hormone fragment bPTH(1 - 37).  Biochem Biophys Res Commun. 2000;  267 213-220
    CrossrefPubMedGoogle Scholar
  • 20 Melliere D, Berrahal D, Perlemuter L, Hindie E, Simon D. Primary hyperparathyroidism. Relationships of symptoms to age, sex, calcemia, anatomical lesions and weight of the glands.  Presse Med. 1995;  24 1889-1993
    PubMedGoogle Scholar
  • 21 Melton L J. Epidemiology of primary hyperparathyroidism.  J Bone Miner Res. 1991;  6 25-30
    PubMedGoogle Scholar
  • 22 Moore K L, Persaud T VN. The Developing Human (Clinically Oriented Embryology). 5th ed. New York; W. B. Saunders Company 2000: 118
    Google Scholar
  • 23 Nobori M, Saiki S, Tanaka N, Harihara Y, Shindo S, Fujimoto Y. Blood supply of parathyroid gland from the superior thyroid artery.  Source Surgery. 1994;  115 417-423
    PubMedGoogle Scholar
  • 24 Okada Y, Mizutani Z, Takeuchi H, Shigeno C, Konishi J, Yoshida O. Preoperative imaging for parathyroid localization in primary hyperparathyroidism.  Int J Urol. 1997;  4 338-442
    PubMedGoogle Scholar
  • 25 Onyja J E, Miles R R, Yang X, Halladay D L, Hale J, Glasebrook A. In vivo demonstration that human parathyroid hormone 1 - 38 inhibits the expression of osteroprotegerin in bone with the kinetics of an immediate early gene.  J Bone Miner Res. 2000;  15 863-871
    PubMedGoogle Scholar
  • 26 Rauth J D, Session R B, Shupe S C, Ziessmann H A. Comparison of Tc-99 m MIBI and TI-201/Tc-99 m pertechnetate for diagnosis of primary hyperparathyroidism.  Clin Nucl Med. 1996;  21 602-608
    CrossrefPubMedGoogle Scholar
  • 27 Roth H J. Elecsys parathyroid hormone (PTH) not detecting large PTH fragment hPTH (7 - 84).  Clin Lab. 2000;  46 295-299
    PubMedGoogle Scholar
  • 28 Rubello D, Saladini G, Casara D, Borsato N, Toniato A, Piotto A, Bernante P, Pelizzo M R. Parathyroid imaging with pertechnetate plus perchlorate/MIBI subtraction scintigraphy: a fast and effective technique.  Clin Nucl Med. 2000;  25 527-531
    CrossrefPubMedGoogle Scholar
  • 29 Shimizu M, Potts J T, Gardella T J. Minimization of parathyroid hormone. Novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor.  J Biol Chem. 2000;  275 21836-21843
    CrossrefPubMedGoogle Scholar
  • 30 Silverberg S J, Shane E, Jacobs T P, Siris E, Bilezikian J P. A 10-year prospective study of primary hyperparathyroidism with and without parathyroid surgery.  N Engl J Med. 1999;  341 1249-1255
    CrossrefPubMedGoogle Scholar
  • 31 Soreide J A, Heerden J A, Grant C S, Lo C Y, Ilstrup D M. Characteristics of patients surgically treated for primary hyperparathyroidism with and without renal stones.  Surgery. 1996;  120 1033-1038
    PubMedGoogle Scholar
  • 32 Thompson N W, Eckhauser F, Harness J. Anatomy of primary hyperparathyroidism.  Surgery. 1982;  92 814-827
    PubMedGoogle Scholar
  • 33 Walgenbach S, Junginger T. Result of bilateral surgical technique in primary hyperparathyroidism.  Zentralbl Chir. 2001;  126 254-260
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Wermers R A, Khosla S, Atkinson E J, Hodgson S F, Fallon W M, Melton III L J. The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965 - 1992.  Ann Int Med. 1997;  126 433-440
    PubMedGoogle Scholar
  • 35 Whitfield J F, Morley P, Willick G E, Isaacs R J, MacLean S, Ross V, Barbier J R, Divieti P, Bringhurst F R. Lactam formation increases receptor binding, adenylyl cyclase stimulation and bone growth stimulation by human parathyroid hormone (hPTH) (1 - 28)NH2.  J Bone Miner Res. 2000;  15 964-970
    PubMedGoogle Scholar
  • 36 Williams J G, Wheeler M H, Aston J P, Brown R C, Woodhead J. The relationship between adenoma weight and intact (1 - 84) parathyroid hormone level in primary hyperparathyroidism.  Am J Surg. 1992;  163 301-304
    CrossrefPubMedGoogle Scholar
  • 37 Yasudo I. Molecular pathogenesis of tumor genesis in sporadic parathyroid adenomas.  J Bone Miner Res. 2002;  20 190-195
    PubMedGoogle Scholar

Dr. Emoke Csupor

The Health Service, Budavar Local Authorities

16/b Maros utca

1122 Budapest

Hungary

Phone: + 3614561031

Fax: + 36 14 56 10 31

Email: ecsupor@freemail.hu

      >